May 2017

New Product - Grazax

Grazax (Timothy grass pollen (Phleum pratense) allergen extract) modifies the immune response to grass pollen induced allergic disease, leading to improvement in disease control and quality of life during subsequent natural allergen exposure. Grazax is indicated for disease modifying treatment of grass pollen (P. pratense or allergens cross reacting with P. pratense) induced allergic rhinitis with or without conjunctivitis in adults, adolescents and children above the age of 5 years. Grazax is contraindicated in adults with uncontrolled asthma or FEV₁ < 70% of predicted value (after adequate pharmacological treatment) at initiation of treatment; in paediatric patients with uncontrolled asthma or FEV₁ < 80% of predicted value (after adequate pharmacological treatment) at initiation of treatment; in patients with malignant or systemic disease affecting the immune system (e.g. autoimmune diseases, immune complex diseases or immune deficiency diseases); in patients with acute severe oral inflammation or oral wounds. Grazax is supplied as 75,000 SQ-T sublingual tablets in packs of 30’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au